Lausanne, Switzerland (ots/PRNewswire) - - Acromegaly and gastroenteropancreatic neuroendocrine tumors (GEP-NETs) are rare diseases that require life-long chronic treatment. Monthly somatostatin analog (SSA) injections are the standard of care as first-line medical treatment. - Debiopharm is developing Debio 4126, a ...
Basel, Switzerland (ots/PRNewswire) - - Roche and Lilly will integrate data from Lilly's connected insulin pen solution into the mySugr app in several countries. - Both companies are dedicated to driving new possibilities to ease the complexity of daily decision making for people with diabetes on insulin pen therapy and their healthcare professionals. - By ...
Basel (ots) - ● Roche and Lilly will integrate data from Lilly’s connected insulin pen solution into the mySugr app in several countries. ● Both companies are dedicated to driving new possibilities to ease the complexity of daily decision making for people with diabetes on insulin pen therapy and their healthcare professionals. ● By collaborating with Lilly, ...
Bagsværd, Denmark (ots/PRNewswire) - This material is intended for global medical media only, excl US For journalistic assessment and preparation before publication. Today, Novo Nordisk announced results from a phase 2 clinical trial of investigational insulin icodec, a once-weekly basal insulin analogue. In the ...
Bagsværd, Denmark (ots/PRNewswire) - This material is intended for global medical media only, excl US. For journalistic assessment and preparation before publication. - A separate real-world study showed that people with type 2 diabetes on two oral antidiabetic drugs who intensified with a glucagon-like peptide-1 ...
Bagsværd, Denmark (ots/PRNewswire) - Novo Nordisk today announced that the New England Journal of Medicine published results of a phase 3 trial evaluating the investigational use of Saxenda® (liraglutide 3.0 mg) in adolescents (aged ...
Barcelona, Spain (ots/PRNewswire) - According to new data from the CONCLUDE head-to-head trial, Tresiba® (insulin degludec) showed an overall lower risk of hypoglycaemia, also known as a hypo or low blood sugar, at a significantly lower HbA1c, compared with insulin glargine U300 in adults with type 2 diabetes ...
Athens, Greece (ots/PRNewswire) - Somapacitan, a novel growth hormone derivative in development for once-weekly administration of growth hormone, matched the therapeutic benefits of once-daily Norditropin® (somatropin) in a phase 2 trial in children with growth hormone deficiency.[1] There are currently no approved ...